Carcinoid Syndrome
26
2
4
13
Key Insights
Highlights
Success Rate
76% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
15.4%
4 terminated out of 26 trials
76.5%
-10.0% vs benchmark
23%
6 trials in Phase 3/4
77%
10 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (26)
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
CardioNETPOL National Registry of Carcinoid Heart Disease
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
Fibrosis in Chronic and Delayed Myocardial Infarction
Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy